Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting

被引:3
|
作者
Konishi, Keiji [1 ,2 ,3 ]
Onozuka, Daisuke [2 ,3 ]
Okubo, Moeka [4 ]
Kasamatsu, Yu [1 ]
Kutsuna, Satoshi [2 ,3 ]
Shirano, Michinori [1 ]
机构
[1] Osaka City Gen Hosp, Dept Infect Dis, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Postinfect Dis Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Grad Sch Med, Dept Infect Control & Prevent, Osaka, Japan
[4] Osaka City Gen Hosp, Dept Pharm, Osaka, Japan
关键词
Antiretroviral therapy; Long-acting antiretroviral therapy; Adherence; Cabotegravir; Rilpivirine; Japanese; TENOFOVIR DISOPROXIL FUMARATE; CABOTEGRAVIR PLUS RILPIVIRINE; HIV-1; INFECTION; OPEN-LABEL; RESISTANT HIV-1; PHASE-3; ADULTS; ALAFENAMIDE; EFFICACY; SAFETY;
D O I
10.1186/s12879-024-09904-x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Antiretroviral therapy (ART) for HIV infection has evolved substantially. The development of long-acting drugs, such as cabotegravir (CAB) and rilpivirine (RPV) might improve treatment satisfaction among people living with HIV (PLWH). The real-world effectiveness of long-acting ART and its effect on patient satisfaction needs to be assessed. This study investigated antiviral effectiveness and treatment satisfaction in PLWH who switched from conventional to long-acting ART (CAB + RPV). Methods This prospective cohort study included PLWH aged 18 years and older who switched to CAB + RPV and received the injections every 8 weeks between June 2022 and May 2023, after a 4-week oral lead-in phase. The eligibility criteria included viral suppression, absence of hepatitis B virus (HBV) DNA, and no prior RPV resistance mutations. Clinical data, including renal, lipid, and glucose biomarker levels, were monitored from the baseline to 44 weeks after switching. Treatment satisfaction was assessed using the HIV Treatment Satisfaction Questionnaire. A linear mixed-effects model was used to estimate changes in clinical data from baseline. Results Thirty-eight male participants were enrolled. Some participants had detectable levels of viral replication; however, all participants maintained viral suppression (HIV-RNA < 50 copies/mL) at 44 weeks and no cases of virological failure were detected. The creatinine level decreased by - 0.04 mg/dL (95% confidence interval [CI]: - 0.07 to - 0.01), lipid and glucose profiles remained stable, and treatment satisfaction increased by 6.6 points (95% CI: 2.4 to 10.8) after switching to CAB + RPV. Conclusions Long-acting ART provides effective viral suppression and enhances treatment satisfaction in PLWH switching from conventional ART. Long-acting ART can improve patient well-being; however, patient selection and monitoring to prevent HBV-related complications are important.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Real-world effectiveness of aripiprazole long-acting injectable
    Pappa, S.
    Barnett, J.
    Mason, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S472 - S472
  • [2] Real-world patient experience of long-acting injectable antiretroviral therapy (LAI-ART): the voice of young adults with perinatally acquired HIV (YAPAH)
    Bilinska, Julia
    Tyler, Stephanie
    Mukela, Audrey
    Barchi, Will
    Accoroni, Alex
    Chilton, Daniella
    HIV MEDICINE, 2022, 23 : 72 - 72
  • [3] CAB plus RPV long-acting antiretroviral therapy: Real world data from an Italian single center in Rome
    Iannone, V.
    Lombardi, F.
    Salvo, P. F.
    Farinacci, D.
    Baldin, G.
    Carbone, A.
    Petrucci, M.
    Onorati, F.
    Visconti, E.
    Di Giambenedetto, S.
    HIV MEDICINE, 2023, 24 : 123 - 124
  • [4] Effectiveness of long-acting injectables and clozapine in a real-world setting during the early-stages of psychotic illness
    Ostinelli, E. G.
    Guanella, E.
    Cavallotti, S.
    Casetta, C.
    D'Agostino, A.
    EUROPEAN PSYCHIATRY, 2016, 33 : S105 - S105
  • [5] Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
    Hodgson, Richard E.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 517 - 524
  • [6] Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
    Kim, Hye Ok
    Seo, Gi Hyeon
    Lee, Boung Chul
    ANNALS OF GENERAL PSYCHIATRY, 2020, 19 (01)
  • [7] Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
    Hye Ok Kim
    Gi Hyeon Seo
    Boung Chul Lee
    Annals of General Psychiatry, 19
  • [8] Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study
    Antonio Garcia-Carmona, Juan
    Simal-Aguado, Jorge
    Pilar Campos-Navarro, Maria
    Valdivia-Munoz, Francisco
    Galindo-Tovar, Alejandro
    CLINICAL DRUG INVESTIGATION, 2020, 40 (05) : 459 - 468
  • [9] Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study
    Juan Antonio García-Carmona
    Jorge Simal-Aguado
    María Pilar Campos-Navarro
    Francisco Valdivia-Muñoz
    Alejandro Galindo-Tovar
    Clinical Drug Investigation, 2020, 40 : 459 - 468
  • [10] Compliance, therapeutic alliance and patient satisfaction with long-acting risperidone
    Schreiner, A
    Pajonk, FG
    EUROPEAN PSYCHIATRY, 2005, 20 : S77 - S77